Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
|Webcasts|May 18, 2020
Bulletproof your Supply Chain: Hope for the Best, Prepare for the Worst
Author(s)Thermo Fisher Scientific
Learn from the experts on how to best combine supply-chain management and logistics expertise to build a nimble and efficient operation that can help to mitigate risks such as those brought on by the COVID-19 pandemic. Live: Monday, May 18, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST On demand available after final airing May 18, 2021 Register free
Register free:
Event Overview:
Incorporating a well-thought out contingency plan is critical when developing a clinical and commercial supply chain. During global uncertainty, such as the COVID-19 pandemic, being properly prepared can help a pharmaceutical company navigate through the increased complexities to deliver its drug to the right place at the right time. Learn from the experts how to best combine supply-chain management and logistics expertise to build a nimble and efficient operation.
Key Learning Objectives:
- Why it is critical to manage, optimize, and streamline a supply chain
- How to incorporate flexibility in planning to overcome potential challenges
- The value of having a contingency plan, even if it is never needed
- How to use a risk-based approach to determine where a contingency plan is needed
Speakers: Michelle Friedman, Program Director, Clinical Supply Optimization Services, Thermo Fisher Scientific
Jason Mieding, Global Leader, Total Transportation Management, Thermo Fisher Scientific
Time and Date: Monday, May 18, 2020 at 11am EDT | 8am PDT | 4pm BST | 5pm CEST
On demand available after final airing May 18, 2021
Sponsor: Thermo Fisher Scientific
Register free:
Related to this article
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trending on Pharmaceutical Technology
1
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
2
CPHI Milan: Packaging and Delivery Decisions Must Reflect Real-World Care
3
Complying with International Pharmacopoeias
4
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
5